Vacuna antirrabica de cerebro de raton lactante: Composicion antigenica y capacidad inmunogena / Suckling mouse brain rabies vaccine: Antigenic composition and immunogenic capacity

Suckling mouse brain (SMB) rabies vaccine is the preparation most widely used in the countries of Latin América and the Caribbean. This vaccine, prepared according to the Fuenzalida and Palacios method, consists of three fixed rabies virus strains (CVS, 51, and 91). However, the World Health Organization recommends that rabies vaccines for human use be prepared using only a single strain of this virus. In order to determine whether any one of the antigens of the SMB vaccine could be eliminated from the preparation, the immunogenic capacity of the standard trivalent SMB vaccine was compared with that of experimental bivalent (CVS-51, CVS-91, and 51-91) and monovalent (CVS, 51, and 91) SMB vaccines. The study was conducted using adult and suckling albino mice provided by the laboratory at the Pan Américan Zoonoses Center, Buenos Aires, Argentina, and different strains of fixed and street rabies virus. The experimental vaccines were prepared using the Fuenzalida-Palacios method. Potency and cross-immunity tests were conducted. The result showed that the trivalent vaccine was the most effective in protecting the mice againg both fixed and street rabies virus infections and also in inducing rapid development of neutralizing antibody at high titers

Vacuna antirrabica de cerebro de raton lactante. Tratamiento humano poseexposición en el Ecuador / Rabies suckling mouse brain vaccine. Postexposure human treatment in Ecuador

At the Leopoldo Izquieta Perez National Institute of Hygiene and Tropical Medicine in Guayaquil, Ecuador, between November 1983 and February 1985 an evaluation was done of the serological response of two groups, of 19 volunteers each, who received rabies suckling mouse brain (SMB) vaccine produced by that institution and quality- controlled by the PAHO/WHO Pan Américan Zoonoses Center. Two postexposure treatment schemes were used: one group received 14 doses of rabies SMB vaccine (one per day) plus three boosters at 10, 20, and 90 days after the last dose of the initial series; the other group recieved six doses (one per day) and two boosters at 20 and 90 days after completing the initial series. It was not possible to demonstrate statistically significant differences between the median titers of the rabies neutralizing antibody in the two groups at 32, 98, and 180 days after the beginning of the two treatments. The results of this study could serve as a basis for the health authorities of Ecuador in their adoption of a limited vaccination scheme that is more innocuous, effective, and economical than the scheme presently applied in that country

Estabilidad de la vacuna antirrabica de cerebro de raton lactante almacenada a distintas temperaturas

Considering that every year some 300 people die of rabies in Latin América and the Caribbean, it is important for the Region to have rabies vaccines that are potent, innocuous, stable, and inexpensive. The type of rabies vaccine most widely used for both human and animal purposes at present is suckling mouse brain (SMB) vaccine. To demonstrate the stability of SMB vaccine at different temperatures, test lots of liquid and lyophilized SMB vaccine were prepared for human and canine use. Samples were then stored at 4oC, 25oC, and 37oC; and their antigenic potency was checked periodically by the NIH test. The average antigenic potency of six test lots of liquid SMB vaccine prepared for human use declined by some 52.3 percent, from an initial average level of 0.8, when stored at 4oC over 15 months. However, all the lots met the minimum potency requirement established by the NIH test at the end of 15 months at 4oC. All six also retained acceptable potency for 30 days when stored at 37oC. Similar patterns were exhibited by lots of liquid vaccine prepared for canine and bovine use

Vacuna antirrabica de cerebro de raton lactante. Tratamiento humano poseexposicion en el Ecuador / Rabies suckling mouse brain vaccine. Postexposure human treatment in Ecuador

At the Leopoldo Izquieta Perez National Institute of Hygiene and Tropical Medicine in Guayaquil, Ecuador, between November 1983 and February 1985 an evaluation was done of the serological response of two groups, of 19 volunteers each, who received rabies suckling mouse brain (SMB) vaccine produced by that institution and quality- controlled by the PAHO/WHO Pan American Zoonoses Center. Two postexposure treatment schemes were used: one group received 14 doses of rabies SMB vaccine (one per day) plus three boosters at 10, 20, and 90 days after the last dose of the initial series; the other group recieved six doses (one per day) and two boosters at 20 and 90 days after completing the initial series. It was not possible to demonstrate statistically significant differences between the median titers of the rabies neutralizing antibody in the two groups at 32, 98, and 180 days after the beginning of the two treatments. The results of this study could serve as a basis for the health authorities of Ecuador in their adoption of a limited vaccination scheme that is more innocuous, effective, and economical than the scheme presently applied in that country

Vacuna antirrábica de cerebro de ratón lactante: Composición antigénica y capacidad inmunógena / Suckling mouse brain rabies vaccine: Antigenic composition and immunogenic capacity

Suckling mouse brain (SMB) rabies vaccine is the preparation most widely used in the countries of Latin America and the Caribbean

This vaccine, prepared according to the Fuenzalida and Palacios method, consists of three fixed rabies virus strains (CVS, 51, and 91). However, the World Health Organization recommends that rabies vaccines for human use be prepared using only a single strain of this virus

In order to determine whether any one of the antigens of the SMB vaccine could be eliminated from the preparation, the immunogenic capacity of the standard trivalent SMB vaccine was compared with that of experimental bivalent (CVS-51, CVS-91, and 51-91) and monovalent (CVS, 51, and 91) SMB vaccines

The study was conducted using adult and suckling albino mice provided by the laboratory at the Pan American Zoonoses Center, Buenos Aires, Argentina, and different strains of fixed and street rabies virus

Potency and cross-immunity tests were conducted

The result showed that the trivalent vaccine was the most effective in protecting the mice againg both fixed and street rabies virus infections and also in inducing rapid development of neutralizing antibody at high titers

The experimental vaccines were prepared using the Fuenzalida-Palacios method

Estabilidad de la vacuna antirrábica de cerebro de ratón lactante almacenada a distintas temperaturas

Considering that every year some 300 people die of rabies in Latin America and the Caribbean, it is important for the Region to have rabies vaccines that are potent, innocuous, stable, and inexpensive. The type of rabies vaccine most widely used for both human and animal purposes at present is suckling mouse brain (SMB) vaccine. To demonstrate the stability of SMB vaccine at different temperatures, test lots of liquid and lyophilized SMB vaccine were prepared for human and canine use. Samples were then stored at 4oC, 25oC, and 37oC; and their antigenic potency was checked periodically by the NIH test. The average antigenic potency of six test lots of liquid SMB vaccine prepared for human use declined by some 52.3 percent, from an initial average level of 0.8, when stored at 4oC over 15 months. However, all the lots met the minimum potency requirement established by the NIH test at the end of 15 months at 4oC. All six also retained acceptable potency for 30 days when stored at 37oC. Similar patterns were exhibited by lots of liquid vaccine prepared for canine and bovine use